Answers are grounded in this paper and cite their sources.
Rapid treatment of prolonged convulsive seizures (PCS), preferably within the first few minutes after onset in most patients, is important to prevent progression to life-threatening status epilepticus (SE) and its associated complications. In community settings, benzodiazepine rescue medication for PCS is often administered by non-medical caregivers to achieve timely seizure control. Until recently, rectally administered diazepam was the only treatment approved by the European Medicines Agency (EMA) for PCS in adults. However, an oromucosal midazolam formulation, which has been approved by the EMA for PCS treatment in paediatric patients for over a decade, has now also received such approval for use in adults. The aim of this narrative review is to describe the role of midazolam oromucosal solution in the management of PCS in adults in community settings in Europe. The approval of midazolam oromucosal solution was supported by pharmacokinetic modelling studies, which extrapolated the efficacy of oromucosal midazolam to adults through exposure matching, alongside European clinical studies where oromucosal midazolam was used as an off-label treatment, thereby demonstrating its effectiveness for treating PCS and SE in adults and paediatric patients. With this approval, adult patients across Europe now have access to an alternative to rectal diazepam that is easy to administer, socially acceptable, and pharmacokinetically appropriate. The increased willingness of caregivers to administer rescue medication by the oromucosal compared with the rectal route should encourage its appropriate use, thus potentially improving outcomes for adults with PCS in Europe. Prolonged convulsive seizures (PCS) can occur in people of all ages, can be difficult to manage, and may begin at home, work, or school. If these seizures last for more than 5 min, they can lead to life-threatening status epilepticus (SE), which may have serious complications. PCS are usually managed with medicines called benzodiazepines, such as midazolam, diazepam and lorazepam, that are often given to the patient by caregivers and family members. Until recently, diazepam administered into the rectum was the only treatment approved by the European Medicines Agency (EMA) for PCS in adults. However, rectal treatments can be difficult to administer and are not suitable to use outside a hospital in adults experiencing seizures because it is not socially acceptable. Since 2011, an effective treatment has been available in Europe to manage PCS in children—a solution of midazolam that can be placed on the gums (called oromucosal midazolam). Recently, this medicine was approved by the EMA for use in adults to manage PCS and prevent SE. Thus, adult patients across Europe now have access to a product that is easier to administer and more socially acceptable than rectal diazepam. Caregivers of people who experience PCS are more confident and prefer to administer rescue medication by the oromucosal than by the rectal route. Therefore, oromucosal midazolam may improve outcomes for adult patients with PCS in Europe.
No takes yet. Share an insight, caveat, or question.
Carreño et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: